Cart (0)
  • No items in cart.
Total
$0
There is a technical issue about last added item. You can click "Report to us" button to let us know and we resolve the issue and return back to you or you can continue without last item via click to continue button.
Search book title
Enter keywords for book title search
Search book content
Enter keywords for book content search
Filters:
FORMAT
BOOKS
PACKAGES
EDITION
to
PUBLISHER
(1)
(326)
(573)
(44)
(234)
(969)
(652)
(2114)
(64)
(92448)
(54)
(541)
(117)
(33)
(21)
(20)
(93277)
(3)
(17)
(1)
(351)
(300)
(6217)
(240)
(16)
(5)
(1635)
(16)
(19)
(28)
(4)
 
(6)
(7)
(115)
(3)
(57)
(5)
(5)
(1)
(1)
(2)
(25)
(26)
(27)
(13)
(61)
(24)
(22)
(7)
(8)
(20)
(1)
(3)
(50)
(6)
(31)
CONTENT TYPE
 Act
 Admin Code
 Announcements
 Bill
 Book
 CADD File
 CAN
 CEU
 Charter
 Checklist
 City Code
 Code
 Commentary
 Comprehensive Plan
 Conference Paper
 County Code
 Course
 DHS Documents
 Document
 Errata
 Executive Regulation
 Federal Guideline
 Firm Content
 Guideline
 Handbook
 Interpretation
 Journal
 Land Use and Development
 Law
 Legislative Rule
 Local Amendment
 Local Code
 Local Document
 Local Regulation
 Local Standards
 Manual
 Model Code
 Model Standard
 Notice
 Ordinance
 Other
 Paperback
 PASS
 Periodicals
 PIN
 Plan
 Policy
 Product
 Product - Data Sheet
 Program
 Provisions
 Requirements
 Revisions
 Rules & Regulations
 Standards
 State Amendment
 State Code
 State Manual
 State Plan
 State Standards
 Statute
 Study Guide
 Supplement
 Sustainability
 Technical Bulletin
 All
  • BSI
    PAS 157:2015 Evaluation of materials of biological origin used in the production of cell-based medicinal products. Guide
    Edition: 2015
    $143.57
    / user per year

Description of PAS 157:2015 2015

This PAS gives guidance on the evaluation of materials of biological origin used in the production of cell-based medicinal products for human use; including those gene therapy products whereby the cells form part of the final drug product.

This PAS also includes guidance on identifying, assessing and controlling risks to patients associated with materials of biological origin.

This PAS covers the evaluation of all materials of biological origin that come into contact with the cellular active substance.

This PAS focuses primarily on materials of human and animal origin and their potential impurities and contaminants. However, reagents derived from diverse biological sources including plants, insects and marine organisms are also used in the development of cell-based medicinal products. Therefore the fundamental principles of risk management also apply for these materials.

This PAS also covers legislation for cell-based medicinal products and is intended for developers who wish to undertake clinical trials and/or license products in both the EU and the US.

This PAS does not cover the selection, assessment or control of cellular active substances, nor the starting materials as defined in Directive 2001/83/EC [1] and excipients. However, it is anticipated that these are still covered by general risk management procedures.

This PAS does not cover biological materials that are used in the development of any other biological medicinal product.

This PAS is applicable for product developers at all stages of development; however maximum benefits can be gained by the implementation of recommendations in this PAS in the early stages of development.

This PAS is intended for use by organizations and individuals with an interest in the development of cell-based medicinal products for clinical applications.



About BSI

BSI Group, also known as the British Standards Institution is the national standards body of the United Kingdom. BSI produces technical standards on a wide range of products and services and also supplies certification and standards-related services to businesses.

X